Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences Inc (NQ: ENVB )

1.490 -0.080 (-5.10%)
Streaming Delayed Price Updated: 3:58 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,901
Open 1.580
Bid (Size) 1.490 (2)
Ask (Size) 1.520 (10)
Prev. Close 1.570
Today's Range 1.460 - 1.660
52wk Range 1.300 - 6.980
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
From Enveric Biosciences
Via Business Wire

Performance

YTD
-35.22%
-35.22%
1 Month
-17.22%
-17.22%
3 Month
-30.70%
-30.70%
6 Month
-63.57%
-63.57%
1 Year
-50.33%
-50.33%

More News

Read More
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
From Enveric Biosciences
Via Business Wire
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
From Enveric Biosciences
Via Business Wire
Enveric Biosciences' Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials
Via Benzinga
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
Via Benzinga
Enveric Biosciences to Present at the Centurion One 5th Global Summit
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Via Benzinga
Exposures Product Safety
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
From Enveric Biosciences
Via Business Wire
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
From Enveric Biosciences
Via Business Wire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Via Benzinga
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
From Enveric Biosciences
Via Business Wire
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Via Benzinga
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here
Via Benzinga
Topics Derivatives Intellectual Property
Exposures Derivatives Intellectual Property
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
From Enveric Biosciences
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.